New-Onset IBD and IL-17 Inhibitors: What Is the Risk?

New-Onset IBD and IL-17 Inhibitors: What Is the Risk? — Underlying inflammatory disease severity should be taken into account. by Nancy Walsh …

  • You already voted!
  • Read More

Get Unlimited Free Access

Join 20,000 other readers who rate their headlines through us